Catheter ablation of atrial fibrillation in patients with systolic left ventricular dysfunction

Atrial fibrillation (AF) is the most common arrhythmia among the adult population, affecting up to 2% of the population. Among patients with chronic heart failure (CHF), the prevalence of AF reaches 12.3%. The presence of common risk factors and pathophysiological mechanisms of AF and CHF development lead to the frequent combination of these two pathologies, which has a negative impact on the course of the underlying disease and further prognosis, increasing the chances of adverse outcomes such as stroke, myocardial infarction, and cardiovascular mortality. The results of most randomized studies indicate that interventional treatment of AF in patients with CHF and intermediate to low left ventricular ejection fraction (LV) contributes to reducing the functional class of CHF and improving quality of life, but at the same time, there is currently no consensus on the effectiveness, safety, and extent of catheter intervention. In this review, we attempted to summarize the literature data regarding the outcomes of interventional treatment of AF in patients with systolic LV dysfunction.

1. Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). European Heart Journal 2020;00:1-125. https://doi.org/10.1093/eurheartj/ehaa612.

2. Mareev YuV, Polyakov DS, Vinogradova NG, et al. Epidemiology of atrial fibrillation in a representative sample of the European part of the Russian Federation. Analysis of EPOCH-CHF study. Kardiologiia. 2022;62(4): 12-19. (In Russ.).

3. Russian Society of Cardiology (RSC) 2020 Clinical practice guidelines for Chronic heart failure. Russian Journal of Cardiology. 2020;25(11): 4083 (In Russ.). https://doi.org/10.15829/1560-4071-2020-4083.

4. Polyakov DS, Fomin IV, Belenkov YuN, et al. Chronic heart failure in the Russian Federation: what has changed over 20 years of follow-up? Results of the EPOCH-CHF study. Kardiologiia. 2021;61(4): 4-14 (In Russ.).

5. Shishkina EA, Khlynova OV, Lebedeva YI, et al. Atrial fibrillation and myocardial infarction: clinical-pathogenetic relationships and impact on prognosis. Doctor.Ru. 2023;22(8): 23-28. (In Russ.). https://doi.org/10.31550/1727-2378-2023-22-8-23-28.

6. Osmolovskaya YF, Romanova NV, Zhirov IV, et al. Epidemiology and management of heart failure patients with atrial fibrillation. Medical Council. 2016;(10): 93-97. (In Russ.).

7. Larina VN, Skiba IK, Skiba AS, et al. Heart failure and atrial fibrillation: updates and perspectives. Russian Journal of Cardiology. 2022;27(7): 5018 (In Russ.).

8. Zhirov IV, Safronova NV, Osmolovskaya YuF, et al. Prognostic value of atrial fibrillation in patients with heart failure and different left ventricular ejection fraction: results of the multicenter RIF-CHF register. Russian Journal of Cardiology. 2021;26(1): 4200. (In Russ.).

9. Khan MN, Jaïs P, Cummings J, et al. Pulmonary-vein isolation for atrial fibrillation in patients with heart failure. N Engl J Med. 2008;359(17):1778-85. https://doi.org/10.1056/NEJMoa0708234.

10. Jones DG, Haldar SK, Hussain W, et al. A randomized trial to assess catheter ablation versus rate control in the management of persistent atrial fibrillation in heart failure. J Am Coll Cardiol. 2013;61(18): 1894-903. https://doi.org/10.1016/j.jacc.2013.01.069.

11. Hunter RJ, Berriman TJ, Diab I et al. A randomized controlled trial of catheter ablation versus medical treatment of atrial fibrillation in heart failure (the CAMTAF trial). Circ Arrhythm Electrophysiol. 2014;7(1): 31-8. https://doi.org/10.1161/CIRCEP.113.000806.

12. Di Biase L, Mohanty P, Mohanty S, et al. Ablation Versus Amiodarone for Treatment of Persistent Atrial Fibrillation in Patients With Congestive Heart Failure and an Implanted Device: Results From the AATAC Multicenter Randomized Trial. Circulation. 2016;133(17): 1637-44. https://doi.org/10.1161/CIRCULATIONAHA.115.019406.

13. Prabhu S, Taylor AJ, Costello BT, et al. Catheter Ablation Versus Medical Rate Control in Atrial Fibrillation and Systolic Dysfunction: The CAMERA-MRI Study. J Am Coll Cardiol. 2017;70(16): 1949-1961. https://doi.org/10.1016/j.jacc.2017.08.041.

14. Marrouche NF, Brachmann J, Andresen D, et al. Catheter Ablation for Atrial Fibrillation with Heart Failure. N Engl J Med. 2018;378(5):417-427. https://doi.org/10.1056/NEJMoa1707855.

15. Packer DL, Mark DB, Robb RA, et al. Effect of Catheter Ablation vs Antiarrhythmic Drug Therapy on Mortality, Stroke, Bleeding, and Cardiac Arrest Among Patients With Atrial Fibrillation: The CABANA Randomized Clinical Trial. JAMA. 2019;321(13): 1261-1274. https://doi.org/10.1001/jama.2019.0693.

16. Kuck KH, Merkely B, Zahn R, et al. Catheter Ablation Versus Best Medical Therapy in Patients With Persistent Atrial Fibrillation and Congestive Heart Failure: The Randomized AMICA Trial. Circ Arrhythm Electrophysiol. 2019;12(12): e007731. https://doi.org/10.1161/CIRCEP.119.007731.

17. Parkash R, Wells GA, Rouleau J, et al. Randomized Ablation-Based Rhythm-Control Versus Rate-Control Trial in Patients With Heart Failure and Atrial Fibrillation: Results from the RAFT-AF trial. Circulation. 2022;145(23): 1693-1704. https://doi.org/10.1161/CIRCULATIONAHA.121.057095.

18. Verhaert DVM, Brunner-La Rocca HP, van Veldhuisen DJ, et al. The bidirectional interaction between atrial fibrillation and heart failure: consequences for the management of both diseases. Europace. 2021;23(23 Suppl 2): ii40-ii45. https://doi.org/10.1093/europace/euaa368.

19. Gallagher JJ, Svenson RH, Kasell JH, et al. Catheter technique for closed-chest ablation of the atrioventricular conduction system. N Engl J Med. 1982;306(4): 194-200. https://doi.org/10.1056/NEJM198201283060402.

20. Scheinman MM, Morady F, Hess DS, et al. Catheter-induced ablation of the atrioventricular junction to control refractory supraventricular arrhythmias. JAMA. 1982;248(7): 851-5.

21. Phlips T, Taghji P, El Haddad M, et al. Improving procedural and one-year outcome after contact force-guided pulmonary vein isolation: the role of interlesion distance, ablation index, and contact force variability in the ‘CLOSE’-protocol. Europace. 2018;20(FI_3):f419-f427. https://doi.org/10.1093/europace/eux376.

22. Gasimova N.Z., Shabanov V.V., Safonov N.V., et al. Multipolar mapping in the management of different arrhythmias. Journal of Arrhythmology. 2024;31(1): 110-122. (In Russ.). https://doi.org/10.35336/VA-1297.

23. Chen MS, Marrouche NF, Khaykin Y, et al. Pulmonary vein isolation for the treatment of atrial fibrillation in patients with impaired systolic func-tion. J Am Coll Cardiol. 2004;43: 1004-1009.

24. Sugumar H, Prabhu S, Costello B, et al. Catheter Ablation Versus Medication in Atrial Fibrillation and Systolic Dysfunction: Late Outcomes of CAMERA-MRI Study. JACC Clin Electrophysiol. 2020;6(13): 1721-1731. https://doi.org/10.1016/j.jacep.2020.08.019.

25. Packer DL, Piccini JP, Monahan KH, et al. Ablation Versus Drug Therapy for Atrial Fibrillation in Heart Failure: Results From the CABANA Trial. Circulation. 2021;143(14):1377-1390. https://doi.org/10.1161/CIRCULATIONAHA.120.050991.

26. MacDonald MR, Connelly DT, Hawkins NM, et al. Radiofrequency ablation for persistent atrial fibrillation in patients with advanced heart failure and severe left ventricular systolic dysfunction: a randomised controlled trial. Heart. 2011;97(9):740-7. https://doi.org/10.1136/hrt.2010.207340.

27. Hagens VE, Crijns HJ, Van Veldhuisen DJ, et al. RAte Control versus Electrical cardioversion for persistent atrial fibrillation study group. Rate control versus rhythm control for patients with persistent atrial fibrillation with mild to moderate heart failure: results from the RAte Control versus Electrical cardioversion (RACE) study. Am Heart J. 2005;149(6): 1106-11. https://doi.org/10.1016/j.ahj.2004.11.030.

28. Olshansky B, Rosenfeld LE, Warner AL, et al. The Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study: approaches to control rate in atrial fibrillation. J Am Coll Cardiol. 2004;43(7):1201-8. https://doi.org/10.1016/j.jacc.2003.11.032.

29. Roy D, Talajic M, Nattel S, et al. Atrial Fibrillation and Congestive Heart Failure Investigators. Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med. 2008;358(25): 2667-77. https://doi.org/10.1056/NEJMoa0708789.

30. Bunch TJ, May HT, Bair TL, et al. Five-year outcomes of catheter ablation in patients with atrial fibrillation and left ventricular systolic dysfunction. J Cardiovasc Electrophysiol. 2015;26(4): 363-370. https://doi.org/10.1111/jce.12602.

31. Geng J, Zhang Y, Wang Y, et al. Catheter ablation versus rate control in patients with atrial fibrillation and heart failure: A multicenter study. Medicine (Baltimore). 2017;96(49): e9179. https://doi.org/10.1097/MD.0000000000009179.

32. Ichijo S, Miyazaki S, Kusa S, et al. Impact of catheter ablation of atrial fibrillation on long-term clinical outcomes in patients with heart failure. J Cardiol. 2018 Sep;72(3): 240-246. https://doi.org/10.1016/j.jjcc.2018.02.012.

33. Rillig A, Makimoto H, Wegner J, et al. Six-Year Clinical Outcomes After Catheter Ablation of Atrial Fibrillation in Patients With Impaired Left Ventricular Function. J Cardiovasc Electrophysiol. 2015;26(11): 1169-1179. https://doi.org/10.1111/jce.12765.

34. Ullah W, Ling LH, Prabhu S, et al. Catheter ablation of atrial fibrillation in patients with heart failure: impact of maintaining sinus rhythm on heart failure status and long-term rates of stroke and death. Europace. 2016;18(5): 679-86. https://doi.org/10.1093/europace/euv440.

35. Kosiuk J, Nedios S, Darma A, et al. Impact of single atrial fibrillation catheter ablation on implantable cardioverter defibrillator therapies in patients with ischaemic and non-ischaemic cardiomyopathies. Europace. 2014;16(9): 1322-6. https://doi.org/10.1093/europace/euu018.

36. Wang M, Cai S, Ding W, et al. Efficacy and effects on cardiac function of radiofrequency catheter ablation vs. direct current cardioversion of persistent atrial fibrillation with left ventricular systolic dysfunction. PLoS One. 2017;12(3): e0174510. https://doi.org/10.1371/journal.pone.0174510.

37. Pott A, Jäck S, Schweizer C, et al. Atrial fibrillation ablation in heart failure patients: improved systolic function after cryoballoon pulmonary vein isolation. ESC Heart Fail. 2020;7(5):2258-2267. https://doi.org/10.1002/ehf2.12735.